All In Biotech

Investigational drug · Phase 2

PL8177

Also called: Active study medication

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative.

Phase 2

Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "PL8177"

First trial start

2022

Sep 15, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "PL8177", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Ulcerative Colitis
  • Ulcerative Colitis Acute
  • Ulcerative
  • Ulcerative Colitis Flare

Approved drugs for the same conditions: Ulcerative colitis · Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "PL8177" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 14 on PubMed

Also in development for Ulcerative Colitis

  • ZasocitinibTAK- 279, NDI-034858Phase 317 trials

    Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease

  • MK-7240PRA023, TulisokibartPhase 310 trials

    Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease

  • LutikizumabABT-981Phase 38 trials

    AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis

  • DuvakitugSAR447189, TEV-48574 APhase 36 trials

    Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis

  • FilgotinibGS-6034, GLPG0634Phase 36 trials

    Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)

  • ABX464ObefazimodPhase 35 trials

    Abivax S.A. · Ulcerative Colitis, Moderately to Severely Active Crohn Disease

  • brivekimigSAR442970Phase 25 trials

    Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus

  • MORF-057zotemtegrast, LY4268989Phase 24 trials

    Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.